The discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer.
3 months ago

Beigene, Ltd. (($ONC)) announced an update on their ongoing clinical study. BeiGene, Ltd. is conducting a clinical study titled A Phase 1/1b...
1 week ago

BeiGene abandons ociperlimab over poor phase 3 prospects in latest blow to TIGITs ... BeiGene is scrapping ociperlimab over a disappointing phase...
3 months ago

Our CDK4 molecule is designed to be more potent and selective compared to existing treatments. We are aggressively moving towards phase 3 trials in second-line...
1 month ago

Share this article ... The collaboration will leverage nference's proprietary Agentic AI platform to deepen understanding of chronic lymphocytic...
2 months ago

BeiGene is taking a somewhat paradoxical approach to the traditional industry R&D models, essentially building a large early-stage pipeline that enables them...
8 months ago

California-based biotech BeiGene has terminated the clinical development programme for its lung cancer therapy ociperlimab, after an independent...
3 months ago

The global oncology company announced May 27 that it rebranded as BeOne Medicines Ltd. Additionally, the firm's shareholders also approved its...
1 month ago

John Oyler Sells 5,127 Shares of Beigene, Ltd. (NASDAQ:ONC) Stock ... Beigene, Ltd. (NASDAQ:ONC - Get Free Report) CEO John Oyler sold 5,127...
3 weeks ago

BeiGene will no longer invest in its anti-TIGIT therapy ociperlimab, which it had been developing as a treatment for lung cancer, the biotech...
3 months ago